Treatment of Mood Disorders During Pregnancy and Postpartum

Psychiatric Clinics of North America

Volumn 33, Issue 2, 2010, Pages 273-293

  Cohen, Lee S ^a   Wang, Betty ^a   Nonacs, Ruta ^a   Viguera, Adele C ^a   Lemon, Elizabeth L ^a   Freeman, Marlene P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Mood disorders; Postpartum; Pregnancy

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANHEDONIA; ANXIETY DISORDER; BIPOLAR DISORDER; BIRTH DEFECT; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; GUILT; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HOPELESSNESS; HUMAN; MANIA; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PERINATAL DRUG EXPOSURE; PERINATAL PERIOD; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; PUERPERAL DEPRESSION; PUERPERAL PSYCHOSIS; PUERPERIUM; PULMONARY HYPERTENSION; REVIEW; SELF ESTEEM; SUICIDAL IDEATION; TERATOGENESIS;

ADULT; FEMALE; HUMANS; MOOD DISORDERS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; TIME FACTORS;

EID: 77951494094     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.02.001     Document Type: Review

References (139)

1. Zajicek E. Psychiatric problems during pregnancy. Pregnancy: a psychological and social study 1981, 57-73. Academic, London. S. Wolkind, E. Zajicek (Eds.).
2. Evans J., Heron J., Francomb H., et al. Cohort study of depressed mood during pregnancy and after childbirth. Br Med J 2001, 323:257-260.
3. Cohen L.S., Sichel D.A., Dimmock J.A., et al. Impact of pregnancy on panic disorder: a case series. J Clin Psychiatry 1994, 55:284-288.
4. Cohen L.S., Sichel D.A., Faraone S.V., et al. Course of panic disorder during pregnancy and the puerperium: a preliminary study. Biol Psychiatry 1996, 39:950-954.
5. Cohen L.S., Altshuler L.L., Harlow B.L., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006, 295:499-507.
6. O'Hara M.W. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986, 43:569-573.
7. Frank E., Kupfer D.J., Jacob M., et al. Pregnancy related affective episodes among women with recurrent depression. Am J Psychiatry 1987, 144:288-293.
8. Kessler R.C., McGonagle K.A., Swartz M., et al. Sex and depression in the national comorbidity survey I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29:85-96.
9. Eaton W.W., Kessler R.C., Wittchen H.U., et al. Panic and panic disorder in the United States. Am J Psychiatry 1994, 151:413-420.
10. Orr S., Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995, 17:165-171.
11. Steer R.A., Scholl T.O., Hediger M.L., et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992, 45:1093-1099.
12. Wisner K.L., Sit D.K., Hanusa B.H., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166(5):557-566.
13. Kupfer D., Frank E., Perel J., et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992, 49(10):769-773.
14. Suppes T., Baldessarini R.J., Faedda G.L., et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991, 48:1082-1088.
15. Dencker S.J., Malm U., Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986, 73:181-185.
16. Roy-Byrne P.P., Dager S.R., Cowley D.S., et al. Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: alprazolam versus diazepam. Am J Psychiatry 1989, 146:860-865.
17. Neziroglu F., Anemone R., Yaryura-Tobias J.A. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992, 149:947-950.
18. Wisner K.L., Zarin D.A., Holmboe E.S., et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000, 157:1933-1940.
19. Viguera A.C., Nonacs R., Cohen L.S., et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000, 157:179-184.
20. Viguera A.C., Whitfield T., Baldessarini R.J., et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007, 164:1817-1824. [quiz: 923].
21. Flynn H.A., O'Mahen H.A., Massey L., et al. The impact of a brief obstetrics clinic-based intervention on treatment use for perinatal depression. J Womens Health (Larchmt) 2006, 15:1195-1204.
22. Marcus S.M., Flynn H.A. Depression, antidepressant medication, and functioning outcomes among pregnant women. Int J Gynaecol Obstet 2008, 100:248-251.
23. Frautschi S., Cerulli A., Maine D. Suicide during pregnancy and its neglect as a component of maternal mortality. Int J Gynaecol Obstet 1994, 47:275-284.
24. Appleby L. Suicide during pregnancy and in the first postnatal year. BMJ 1991, 302:137-140.
25. Marzuk M., Tardiff K., Leon A.C., et al. Lower risk of suicide during pregnancy. Am J Psychiatry 1997, 154:122-123.
26. Altshuler L., Cohen L.S., Moline M., et al. Treatment of depression in women: a summary of the expert consensus guidelines. J Psychiatr Pract 2001, 7(3):185-208.
27. Cohen L., Altshuler L., Heller V., et al. Psychotropic drug use in pregnancy. The practitioner's guide to psychoactive drugs 1998, 417-440. Plenum Publishing Corporation, New York. G.A. Bassuk (Ed.).
28. Cohen L.S., Rosenbaum J. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998, 59:18-28.
29. Cott A., Wisner K. Psychiatric disorders during pregnancy. Int Rev Psychiatry 2003, 15:217-230.
30. Einarson T.R., Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005, 14:823-827.
31. Hallberg P., Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005, 25:59-73.
32. Altshuler L.L., Cohen L., Szuba M.P., et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996, 153:592-606.
33. Cohen L., Altshuler L. Pharmacologic management of psychiatric illness during pregnancy and the postpartum period. The psychiatric clinics of North America annual of drug therapy 1997, 21-60. WB Saunders Company, Philadelphia. D. Dunner, J. Rosenbaum (Eds.).
34. Wisner K.L., Gelenberg A.J., Leonard H., et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999, 282:1264-1269.
35. Pastuszak A., Schick-Boschetto B., Zuber C., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993, 269:2246-2248.
36. Altshuler L.L., Hendrick V.C. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol 1996, 16:78-80.
37. Chambers C., Johnson K., Dick L., et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
38. Nulman I., Rovet J., Stewart D., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336:258-262.
39. Kulin N., Pastuszak A., Sage S., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998, 279:609-610.
40. Einarson A., Fatoye B., Sarkar M., et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001, 158:1728-1730.
41. Alwan S., Reefhuis J., Rasmussen S.A., et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692.
42. Louik C., Lin A.E., Werler M.M., et al. First-trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356:2675-2683.
43. Pregnancy and Lactation Labeling Available at:, Accessed February 3, 2010. http://www.fda.gov/CDER/regulatory/pregnancy_labeling/default.htm.
44. Yonkers K.A., Wisner K.L., Stewart D.E., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31:403-413.
45. Freeman M., Davis M., Sinha P., et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008, 110(1-2):142-148.
46. Beck A.T., Rush A.J., Shaw B.F., et al. Cognitive therapy of depression 1979, Guilford, New York.
47. Klerman G.L., Weissman M.M., Rounsaville B.J., et al. Interpersonal psychotherapy of depression 1984, Basic Books Inc Publishers, New York.
48. Spinelli M. Interpersonal psychotherapy for depressed antepartum women: a pilot study. Am J Psychiatry 1997, 154:1028-1030.
49. Cohen L.S., Altshuler L.L., Stowe Z.N., et al. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study. Psychother Psychosom 2004, 73:255-258.
50. Brandes M., Soares C.N., Cohen L.S. Postpartum onset obsessive-compulsive disorder: diagnosis and management. Arch Womens Ment Health 2004, 7:99-110.
51. Heikkinen T., Ekblad U., Palo P., et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003, 73:330-337.
52. Hostetter A., Stowe Z.N., Strader J.R., et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000, 11:51-57.
53. Freeman M.P., Nolan P.E., Davis M.F., et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008, 28:646-653.
54. Sit D.K., Perel J.M., Helsel J.C., et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008, 69:652-658.
55. Ericson A., Källén B., Wilhom B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55:503-508.
56. New safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. 2005. Available at: Accessed June 15, 2006. http://www.gsk.ca/en/health_info/PAXIL_PregnancyDHCPL_E-V4.pdf.
57. New safety information regarding paroxetine: second large study shows an increased risk of cardiac defects, over other antidepressants, following first trimester exposure to paroxetine, 2005. Available at: Accessed June 15, 2006. http://www.womensmentalhealth.org/resources/PDFs/GSK_Canada_Paxil_Letter.pdf.
58. Gentile S. Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions. CNS Spectr 2008, 13:960-966.
59. Einarson A., Pistelli A., DeSantis M., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008, 165:749-752.
60. Updated preliminary report on bupropion and other antidepressants, including paroxetine, in pregnancy and the occurrence of cardiovascular and major congenital malformation 2005. Available at: Accessed February 3, 2010. http://www.gsk.com/media/paroxetine/ingenix_study.pdf.
61. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005, 192:932-936.
62. Cole J.A., Modell J.G., Haight B.R., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:474-484.
63. Verbeeck W., Tuinier S., Bekkering G.E. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther 2009, 26:170-184.
64. Humphreys C., Garcia-Bournissen F., Ito S., et al. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician 2007, 53:1153-1155.
65. Henshaw S. Unintended pregnancy in the United States. Fam Plann Perspect 1998, 30:24-29.
66. Djulus J., Koren G., Einarson T.R., et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006, 67:1280-1284.
67. Krauer B. Pharmacotherapy during pregnancy: emphasis on pharmacokinetics. Drug therapy during pregnancy 1985, 9-31. Butterworths, London. T.K. Eskes, M. Finster (Eds.).
68. Jeffries W.S., Bochner F. The effect of pregnancy on drug pharmacokinetics. Med J Aust 1988, 149:675-677.
69. Wisner K., Perel J., Wheeler S. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993, 150:1541-1542.
70. Zeskind P., Stephens L. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004, 113:368-375.
71. Simon G.E., Cunningham M.L., Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002, 159:2055-2061.
72. Nulman I., Rovet J., Stewart D.E., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002, 159:1889-1895.
73. Suri R., Altshuler L., Hendrick V., et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004, 7:193-200.
74. Levinson-Castiel R., Merlob P., Linder N., et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006, 160:173-176.
75. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-587.
76. Källén B., Otterblad O.P. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007, 79:301-308.
77. Andrade S.E., McPhillips H., Loren D., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009, 18:246-252.
78. Hernandez-Diaz S., Van Marter L.J., Werler M.M., et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007, 120:e272-e282.
79. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005, 293:2372-2383.
80. Misri S., Reebye P., Kendrick K., et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006, 163:1026-1032.
81. Goldstein H., Weinberg J., Sankstone M. Shock therapy in psychosis complicating pregnancy, a case report. Am J Psychiatry 1941, 98:201-202.
82. Impasato D.J., Gabriel A.R., Lardara M. Electric and insulin shock therapy during pregnancy. Dis Nerv Syst 1964, 25:542-546.
83. Remick R.A., Maurice W.L. ECT in pregnancy. Am J Psychiatry 1978, 135:761-762. [letter].
84. Miller L.J. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994, 45:444-450.
85. Wise M.G., Ward S.C., Townsend-Parchman W., et al. Case report of ECT during high-risk pregnancy. Am J Psychiatry 1984, 141:99-101.
86. Repke J.T., Berger N.G. Electroconvulsive therapy in pregnancy. Obstet Gynecol 1984, 63:39S-40S.
87. Sherer D.M., D'Amico L.D., Warshal D.P., et al. Recurrent mild abruption placentae occurring immediately after repeated electroconvulsive therapy in pregnancy. Am J Obstet Gynecol 1991, 165:652-653.
88. Ferrill M.J., Kehoe W.A., Jacisin J.J. ECT during pregnancy: physiologic and pharmacologic considerations. Convuls Ther 1992, 8:186-200.
89. Anderson E.L., Reti I.M. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009, 71:235-242.
90. Viguera A.C., Cohen L.S., Baldessarini R.J., et al. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002, 47:426-436.
91. Faedda G.L., Tondo L., Baldessarini R.J., et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993, 50:448-455.
92. Tohen M., Waternaux C.M., Tsuang M.T. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990, 47:1106-1111.
93. Suppes T., Baldessarini R., Faedda G., et al. Discontinuation of maintenance treatment in bipolar disorder: Risks and implications. Harv Rev Psychiatry 1993, 1:131-144.
94. Newport D.J., Stowe Z.N., Viguera A.C., et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008, 10:432-436.
95. Cohen L.S., Heller V.L., Rosenbaum J.F. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989, 30:25-33.
96. Weinstein M.R., Goldfield M.D. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975, 132:529-531.
97. Schou M., Goldfield M.D., Weinstein M.R., et al. Lithium and pregnancy, I: Report from the register of lithium babies. Br Med J 1973, 2:135-136.
98. Cohen L.S., Friedman J.M., Jefferson J.W., et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994, 271:146-150.
99. Tennis P. Preliminary results on pregnancy outcome in women using lamotrigine. Epilepsia 2002, 43:1161-1167.
100. Messenheimer J, Wiel J. Thirteen year interim results from an international observational study of pregnancy outcomes following exposure to lamotrigine. In: 58th annual meeting of the American Academy of Neurology. San Diego (CA), April 1-8, 2006.
101. Cunnington M., Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005, 64:955-960.
102. Meador K.J., Baker G.A., Finnell R.H., et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006, 67:407-412.
103. Holmes LB, Wyszynski DF, Baldwin EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. In: 46th annual meeting of the Teratology Society. Tucson (AZ), June 24-29, 2006.
104. Wyszynski D., Nambisan M., Surve T., et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:291-295.
105. Lammer E.J., Sever L.E., Oakley G.P. Teratogen update: valproic acid. Teratology 1987, 35:465-473.
106. Omtzigt J.G., Los F.J., Grobbee D.E., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42:119-125.
107. Kendell R.E., Chalmers J.C., Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987, 150:662-673.
108. O'Hara M.W. Postpartum depression: causes and consequences 1995, Springer-Verlag, New York.
109. Bratfos O., Haug J.O. Puerperal mental disorders in manic depressive females. Acta Psychiatr Scand 1966, 42:285-294.
110. Reich T., Winokur G. Postpartum psychosis in patients with manic depressive disease. J Nerv Ment Dis 1970, 151:60-68.
111. Davidson J., Robertson E. A follow-up study of postpartum illness. Acta Psychiatr Scand 1985, 71:451-457.
112. Kupfer D.J., Frank E. Relapse in recurrent unipolar depression. Am J Psychiatry 1987, 144:86-88.
113. Dean C., Williams R.J., Brockington I.F. Is puerperal psychosis the same as bipolar manic-depressive disorder? A family study. Psychol Med 1989, 19:637-647.
114. O'Hara M.W., Zekoski E.M., Philipps L.H., et al. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 1990, 99:3-15.
115. Handley S.L., Dunn T.L., Waldron G., et al. Tryptophan, cortisol and puerperal mood. Br J Psychiatry 1980, 136:498-508.
116. Parekh RI. Prospective study of postpartum blues. In: Annual meeting of the American Psychiatric Association. New York, May 6, 1996.
117. Gotlib I.H., Whiffen V.E., Mount J.H., et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum period. J Consult Clin Psychol 1989, 57:269-274.
118. Hendrick V., Altshuler L., Strouse T., et al. Postpartum and nonpostpartum depression: differences in presentation and response to pharmacologic treatment. Depress Anxiety 2000, 11:66-72.
119. Buttolph M.L., Holland A. Obsessive compulsive disorders in pregnancy and childbirth. Obsessive compulsive disorders, theory and management 1990, 89-97. Yearbook Medical Publishers, Chicago. 2nd edition. M. Jenike, L. Baer, W.E. Minichiello (Eds.).
120. Murray L. Postpartum depression and child development. Psychol Med 1997, 27:253-260.
121. Hayworth J., Little B.C., Carter S.B., et al. A predictive study of post-partum depression: some predisposing characteristics. Br J Med Psychol 1980, 53:161-167.
122. Appleby L., Warner R., Whitton A., et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997, 314:932-936.
123. O'Hara M.W., Stuart S., Gorman L.L., et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000, 57:1039-1045.
124. Suri R., Burt V.K., Altshuler L.L., et al. Fluvoxamine for postpartum depression. Am J Psychiatry 2001, 158:1739-1740.
125. Stowe Z.N., Casarella J., Landrey J., et al. Sertraline in the treatment of women with postpartum major depression. Depression 1995, 3:49-55.
126. Cohen L.S., Viguera A.C., Bouffard S.M., et al. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry 2001, 62:592-596.
127. Nonacs R.M., Soares C.N., Viguera A.C., et al. Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol 2005, 8:445-449.
128. Dalton K. Progesterone prophylaxis used successfully in postnatal depression. Practitioner 1985, 229:507-508.
129. Gregoire A.J., Kumar R., Everitt B., et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996, 347:930-933.
130. Gregoire A. Estrogen supplementation in postpartum depression. In: Biennial Conference of the Marcé Society. Cambridge (UK), September 25-28, 1994.
131. Ahokas A., Kaukoranta J., Wahlbeck K., et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 2001, 62:332-336.
132. Cohen L.S., Sichel D.A., Dimmock J.A., et al. Postpartum course in women with preexisting panic disorder. J Clin Psychiatry 1994, 55:289-292.
133. Sichel D.A., Cohen L.S., Rosenbaum J.F., et al. Postpartum onset of obsessive-compulsive disorder. Psychosomatics 1993, 34:277-279.
134. Austin M.P. Puerperal affective psychosis: is there a case for lithium prophylaxis?. Br J Psychiatry 1992, 161:692-694.
135. Stewart D.E., Klompenhouwer J.L., Kendall R.E., et al. Prophylactic lithium in puerperal psychosis: the experience of three centers. Br J Psychiatry 1991, 158:393-397.
136. Sichel DA, Cohen LS, Rosenbaum JF. High dose estrogen prophylaxis in 11 women at risk for recurrent postpartum psychosis and severe non-psychotic depression. In: Annual meeting of the Marcé Society. Einthoven, the Netherlands; November 5, 1993.
137. Cohen L.S., Sichel D.A., Robertson L.M., et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995, 152:1641-1645.
138. Wisner K.L., Wheeler S.B. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry 1994, 45:1191-1196.
139. Wisner P. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry 2001, 62:82-86.